Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Prostacyclin Receptor (IP Receptor) Agonist — Pulmonary Arterial Hypertension

Selexipag

Brand names: Uptravi

Selexipag is an orally active selective prostacyclin receptor (IP receptor) agonist used in the long-term treatment of pulmonary arterial hypertension.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It and its active metabolite selectively stimulate the prostacyclin IP receptor, producing pulmonary vasodilatation and antiproliferative effects on the pulmonary vasculature.

Prescribing in practice

  • The dose is individually titrated upward to the highest tolerated level, as prostacyclin-related effects such as headache, jaw pain, flushing, nausea, diarrhoea and myalgia are common and dose-limiting.
  • Avoid concomitant strong CYP2C8 inhibitors, which markedly increase exposure.
  • Use with caution in significant hepatic impairment.

Monitoring

Monitor tolerability during dose titration and review for prostacyclin-related adverse effects.

Counselling the patient

  • Headache, jaw pain, flushing and gastrointestinal upset are common, especially as the dose is increased.
  • Do not stop treatment abruptly without specialist advice.
  • Report adverse effects so the dose can be adjusted.

Evidence & guidelines

The GRIPHON trial showed selexipag reduced morbidity and mortality events in pulmonary arterial hypertension.

Reference: GRIPHON Trial 2015; NICE TA397 (Selexipag for PAH); ESC/ERS PAH Guidelines 2022; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways